1. Coelho M, Ferreira JJ. Late-stage Parkinson disease. Nat Rev Neurol 2012; 8:435–442.
2. Hawkes CH. Parkinson’s disease and aging: same or different process? Mov Disord 2008; 23:47–53.
3. Jankovic J, Stacy M. Medical management of levodopa-associated motor complications in patients with Parkinson’s disease. CNS Drugs 2007; 21:677–692.
4. Chaudhuri KR, Schapira AH. Non-motor symptoms of Parkinson’s disease: dopaminergic pathophysiology and treatment. Lancet Neurol 2009; 8:464–474.
5. Schrag A, Jahanshahi M, Quinn N. What contributes to quality of life in patients with Parkinson’s disease? J Neurol Neurosurg Psychiatry 2000; 69:308 –312.
6. Georgiev D, Danieli A, Ocepek L, Novak D, ZupancicKriznar N, Trost M, et al. Othello syndrome in patients with Parkinson's disease. Psychiatr Danub 2010; 22:94-98.
7. Ford B. Pain in Parkinson’s disease. Clin Neurosci 1998; 5:63–72.
8. Beiske AG, Loge JH, Ronningen A, Svensson E. Pain in Parkinson’s disease: prevalence and characteristics. Pain 2009; 141: 173e7.
9. Esposito E, Rotilio D, Di Matteo V, Di Giulio C, Cacchio M, Algeri S. A review of specific dietary antioxidants and the effects on biochemical mechanisms related to neurodegenerative processes. Neurobiol Ag 2002; 23: 719–735.
10. Lu Z, Nie G, Belton PS, Tang H, Zhao B. Structure-activity relationship analysis of antioxidant ability and neuroprotective effect of gallic acid derivatives. Neurochem Int 2006; 48:263–274.
11. Tamaddonfard E, Farshid AA, Asri-Rezaee S, Javadi Sh, Khosravi V, Rahman B, et al. Crocin Improved Learning and Memory Impairments in Streptozotocin-Induced Diabetic Rats. Iran J Basic Med Sci 2013; 16:91-100.
12. Betarbet R, Sherer TB, Greenamyre JT. Animal models of Parkinson’s disease. Bioessays 2002; 24:308–318.
13. Hassanzadeh P, Arbabi E, Rostami F. The ameliorative effects of sesamol against seizures, cognitive impairment and oxidative stress in the experimental model of epilepsy. Iran J Basic Med Sci 2014; 17:100-107.
14. Han YS, Zheng WH, Bastianetto S, Chabot JG, Quirion R. Neuroprotective effects of resveratrol againstb-amyloid-induced neurotoxicity in rat hippocampal neurons: involvement of protein kinase C. Br J Pharmacol 2004; 141:997–1005.
15. Hwang DS, Kim HG, Kwon HJ, Cho JH, Lee CH, Lee JM, et al. Dangguijakyak-san, a medicinal herbal formula, protects dopaminergic neurons from 6-hydroxydopamine-induced neurotoxicity. J Ethnopharmacol 2011; 133:934–939.
17. Wada L, Ou B. Antioxidant activity and phenolic content of Oregon caneberries. J Agric Food Chem 2002; 50:3495–3500.
18. Whitley AC, Stoner GD, Darby MV, Walle T. Intestinal epithelial cell accumulation of the cancer preventive polyphenol ellagic acid-extensive binding to protein and DNA. Biochem Pharmacol 2003; 66:907–915.
19. Uzar E, Alp H, Ugur Cevik M, Fırat U, Evliyaoglu O, Tufek A, et al. Ellagic acid attenuates oxidative stress on brain and sciatic nerve and improves histopathology of brain in streptozotocin-induced diabetic rats. Neurol Sci 2012; 33:567–574.
20. Tadaiesky MT, Dombrowski PA, Figueiredo CP, Cargnin-Ferreira E, Da Cunha C, Takahashi RN. Emotional, cognitive and neurochemical alterations in a premotor stage model of Parkinson’s disease. Neuroscience 2008; 156:830-840.
21. Paxinos G, Watson C. The rat brain in stereotaxic coordinates. Australia: Academic Press; 2006.
22. Sarkaki A, Norooz Zare F, Farbood Y, Pileverian AA. Impaired movements in 6-OHDA induced Parkinson’s rat model improves by pomegranate seed hydroalcoholic extract. Health Med 2013; 7(2): 348-358.
23. Sharifi H, Mohajjel Nayebi A, Farajnia S. 8-OH-DPAT (5-HT1A agonist) attenuates 6-hydroxydopamine-induced catalepsy and modulates inflammatory cytokines in rats. Iran J Basic Med Sci 2013; 16:1270-1275.
24. Rizelio V, Szawka RE, Xavier LL, Achaval M, Rigon P, Saur L, et al. Lesion of the subthalamic nucleus reverses motor deficits but not death of nigrostriatal dopaminergic neurons in a rat 6-hydroxydopamine-lesion model of Parkinson's disease. Braz J Med Biol Res 2010; 43: 85-95.
25. Ziegler MG
, Szechtman H
. Relation between motor asymmetry and direction of rotational behaviour under amphetamine and apomorphine in rats with unilateral degeneration of the nigrostriatal dopamine system. Behav Brain Res
26. D'Amour FE, Smith DL. A method of determining loss of pain sensation. J Pharmacol Exp Ther 1941; 27:74–79.
27. Dolatshahi-somehsofla M, Esmaeili-Mahani S, Motamedi F, Haeri A, Ahmadian A. Adrenalectomy potentiates the antinociceptive effects of calcium channel blockers. Pharmacol Biochem Behav 2009; 92:327–334.
28. Lipton SA, Rosenberg PA. Excitatory amino acids as a final common pathway for neurologic disorders. N Engl J Med 1994; 330:613–622.
30. Doulah AH, Rohani AH, Khaksari Haddad M, Motamedi F, Farbood Y, Badavi M, et al. The effect of peripheral administration of growth hormone on AD-like cognitive deficiency in NBM-lesioned rats. Neurosci Lett 2009; 466:47-51.
31. Lin MT, Wu JJ, Chandra A, Tsay BL. Activation of striatal dopamine receptors induces pain inhibition in rats. J Neural Transm 1981; 51(3-4):213–22.
32. Takeda R, Ikeda T, Tsuda F, Abe H, Hashiguchi H, Ishida Y, et al. Unilateral lesions of mesostriatal dopaminergic pathway alter the withdrawal response of the rat hindpaw to mechanical stimulation. Neurosci Res 2005; 52:31–36.
33. Scott DJ, Heitzeg MM, Koeppe RA, Stohler CS, Zubieta JK. Variations in the human pain stress experience mediated by ventral and dorsal basal ganglia dopamine activity. J Neurosci 2006; 26:10789–10795.
34. Lewis SJ, Cools R, Robbins TW, Dove A, Barker RA, Owen AM. Using executive heterogeneity to explore the nature of working memory deficits in Parkinson’s disease. Neuropsychologia 2003; 41:645– 654.
35. Ferro MM, Bellissimo MI, Anselmo-Franci JA, Angellucci ME, Canteras NS, Da Cunha C. Comparison of bilaterally 6-OHDAand MPTP-lesioned rats as models of the early phase of Parkinson’s disease: histological, neurochemical, motor and memory alterations. J Neurosci Methods 2005; 148:78–87.
36. Reksidler AB, Lima MM, Zanata SM, Machado HB, da Cunha C, Andreatini R, et al. The COX-2 inhibitor parecoxib produces neuroprotective effects in MPTP-lesioned rats. Eur J Pharmacol 2007; 560:163–175.
37. Joelving FC, Billeskov R, Christensen JR, West M, Pakkenberg B. Hippocampal neuron and glial cell numbers in Parkinson’s disease: a stereological study. Hippocampus 2006; 16:826–833.
38. Moriarty O, McGuire BE, Finn DP. The effect of pain on cognitive function: A review of clinical and preclinical research. Prog Neurobiol 2011; l93:385–404.
39. Grisart JM, Plaghki LH. Impaired selective attention in chronic pain patients. Eur J Pain 1999; 3:325–333.
40. Tanaka K, Ogawa N, Asanumab M. Molecular basis of 6-hydroxydopamine-induced caspase activations due to increases in oxidative stress in the mouse striatum. Neurosci Lett 2006; 410:85–89.
41. Metz GA, Tse A, Ballermann M, Smith LK, Fouad K. The unilateral 6-OHDA rat model of Parkinson’s disease revisited: an electromyographic and behavioural analysis. Eur J Neurosci 2005; 22:735–744.